BridgeBio Oncology Therapeutics, Inc.
BBOT
$9.05
$0.171.91%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | ||
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 173.38% | -- | -- | 54,186.80% | |
| Total Receivables | 376.54% | -- | -- | -- | |
| Inventory | -- | -- | -- | -- | |
| Prepaid Expenses | 119.72% | -- | -- | -- | |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | |
| Other Current Assets | -- | -- | -- | -- | |
| Total Current Assets | 172.47% | -- | -- | -- | |
|
|
|||||
| Total Current Assets | 172.47% | -- | -- | -- | |
| Net Property, Plant & Equipment | 570.61% | -- | -- | -- | |
| Long-term Investments | -- | -- | -- | -- | |
| Goodwill | -- | -- | -- | -- | |
| Total Other Intangibles | -- | -- | -- | -- | |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | |
| Total Other Assets | 148.12% | -- | -- | -- | |
| Total Assets | 172.90% | -- | -- | -- | |
|
|
|||||
| Total Accounts Payable | -55.30% | -- | -- | -- | |
| Total Accrued Expenses | 152.45% | -- | -- | -- | |
| Short-term Debt | -- | -- | -- | -- | |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | |
| Finance Division Debt Current | -- | -- | -- | -- | |
| Total Finance Division Other Current Liabilities | -85.12% | -- | -- | -- | |
| Total Other Current Liabilities | -85.12% | -- | -- | -- | |
| Total Current Liabilities | 78.96% | -- | -- | -- | |
|
|
|||||
| Total Current Liabilities | 78.96% | -- | -- | -- | |
| Long-Term Debt | -- | -- | -- | -- | |
| Short-term Debt | -- | -- | -- | -- | |
| Capital Leases | -- | -- | -- | -- | |
| Finance Division Debt Non Current | -- | -- | -- | -- | |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | |
| Total Other Liabilities | -- | -- | -- | -- | |
| Total Liabilities | 90.42% | -- | -- | -- | |
|
|
|||||
| Common Stock & APIC | 1,663.17% | -- | -- | -- | |
| Retained Earnings | -60.24% | -- | -- | -- | |
| Treasury Stock & Other | -95.40% | -- | -- | -- | |
| Total Common Equity | 330.13% | -- | -- | -72.98% | |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | |
| Preferred Stock Convertible | -- | -- | -- | -- | |
| Preferred Stock, Others | -- | -- | -- | -- | |
| Total Preferred Equity | -- | -- | -- | 208.34% | |
|
|
|||||
| Total Common Equity | 330.13% | -- | -- | -72.98% | |
| Total Preferred Equity | -- | -- | -- | 208.34% | |
| Total Minority Interest | -- | -- | -- | -- | |
| Total Equity | 184.06% | -- | -- | 1,236.67% | |
|
|
|||||